학술논문
209TiP - CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
Document Type
Abstract
Author
Source
In Annals of Oncology November 2018 29 Supplement 9:ix65-ix65
Subject
Language
ISSN
0923-7534